☒ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended |
☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
Delaware | No. 68-0533453 | |
(State or Other Jurisdiction of Incorporation or Organization) | (I.R.S. Employer Identification No.) |
Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
Common Stock, par value $0.0001 per share | NUWE | Nasdaq Capital Market |
Large accelerated filer ☐ | Accelerated filer ☐ | |
Non-accelerated | Smaller reporting company ☒ | |
Emerging growth company ☐ |
Page Number | ||
PART I—FINANCIAL INFORMATION | ||
Item 1 | 3 | |
3 | ||
4 | ||
5 | ||
6 | ||
7 | ||
Item 2 | 14 | |
Item 3 | 20 | |
Item 4 | 20 | |
PART II—OTHER INFORMATION | ||
Item 1 | ||
Item 1A | 21 | |
Item 2 | 21 | |
Item 3 | 21 | |
Item 4 | 21 | |
Item 5 | 21 | |
Item 6 | 21 |
March 31, 2021 | December 31, 2020 | September 30, 2021 | December 31, 2020 | |||||||||||||
ASSETS | (unaudited) | (unaudited) | ||||||||||||||
Current assets | ||||||||||||||||
Cash and cash equivalents | $ | 27,893 | $ | 14,437 | $ | 28,431 | $ | 14,437 | ||||||||
Accounts receivable | 919 | 905 | 1,069 | 905 | ||||||||||||
Inventories | 2,957 | 2,957 | 2,805 | 2,957 | ||||||||||||
Other current assets | 369 | 237 | 420 | 237 | ||||||||||||
Total current assets | 32,138 | 18,536 | 32,725 | 18,536 | ||||||||||||
Property, plant and equipment, net | 1,219 | 1,200 | 1,265 | 1,200 | ||||||||||||
Operating lease right-of-use asset | 206 | 255 | 105 | 255 | ||||||||||||
Other assets | — | 21 | 0 | 21 | ||||||||||||
TOTAL ASSETS | $ | 33,563 | $ | 20,012 | $ | 34,095 | $ | 20,012 | ||||||||
LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||||||||||
Current liabilities | ||||||||||||||||
Accounts payable | $ | 1,613 | $ | 1,097 | $ | 1,851 | $ | 1,097 | ||||||||
Accrued compensation | 1,245 | 2,192 | 1,771 | 2,192 | ||||||||||||
Current portion of operating lease liability | 212 | 206 | 108 | 206 | ||||||||||||
Current portion of finance lease liability | 24 | 24 | 27 | 24 | ||||||||||||
Other current liabilities | 69 | 66 | 38 | 66 | ||||||||||||
Total current liabilities | 3,163 | 3,585 | 3,795 | 3,585 | ||||||||||||
Operating lease liability | — | 55 | 0 | 55 | ||||||||||||
Finance lease liability | 48 | 54 | 33 | 54 | ||||||||||||
Other Long-term liability | 286 | 0 | ||||||||||||||
Total liabilities | 3,211 | 3,694 | 4,114 | 3,694 | ||||||||||||
Commitments and contingencies | 0 | 0 | ||||||||||||||
Stockholders’ equity | ||||||||||||||||
Series A junior participating preferred stock as of March 31, 2021 and December 31, 2020, par value $0.0001 per share; authorized 30,000 shares, none outstanding | — | — | ||||||||||||||
Series F convertible preferred stock as of both March 31, 2021 and December 31, 2020, par value $0.0001 per share; authorized 127 shares, issued and outstanding 127 shares | — | — | ||||||||||||||
Preferred stock as of both March 31, 2021 and December 31, 2020, par value $0.0001 per share; authorized 39,969,873 shares, none outstanding | — | — | ||||||||||||||
Common stock as of March 31, 2021 and December 31, 2020, par value $0.0001 per share; authorized 100,000,000 shares, issued and outstanding 6,531,942 and 2,736,060, respectively | — | — | ||||||||||||||
Series A junior participating preferred stock as of September 30, 2021 and December 31, 2020, par value $0.0001 per share; authorized 30,000 shares, NaN outstanding | 0 | 0 | ||||||||||||||
Series F convertible preferred stock as of both September 30, 2021 and December 31, 2020, par value $0.0001 per share; authorized 127 shares, issued and outstanding 127 shares | 0 | 0 | ||||||||||||||
Preferred stock as of both September 30, 2021 and December 31, 2020, par value $0.0001 per share; authorized 39,969,873 shares, NaN outstanding | 0 | 0 | ||||||||||||||
Common stock as of September 30, 2021 and December 31, 2020, par value $0.0001 per share; authorized 100,000,000 shares, issued and outstanding 10,537,606 and 2,736,060, respectively | 1 | 0 | ||||||||||||||
Additional paid‑in capital | 268,921 | 249,663 | 278,552 | 249,663 | ||||||||||||
Accumulated other comprehensive loss: | ||||||||||||||||
Foreign currency translation adjustment | (10 | ) | (7 | ) | (10 | ) | (7 | ) | ||||||||
Accumulated deficit | (238,559 | ) | (233,338 | ) | (248,562 | ) | (233,338 | ) | ||||||||
Total stockholders’ equity | 30,352 | 16,318 | 29,981 | 16,318 | ||||||||||||
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $ | 33,563 | $ | 20,012 | $ | 34,095 | $ | 20,012 |
Three months ended September 30, | Nine months ended September 30, | |||||||||||||||
2021 | 2020 | 2021 | 2020 | |||||||||||||
Net sales | $ | 1,853 | $ | 1,904 | $ | 6,279 | $ | 5,397 | ||||||||
Cost of goods sold | 733 | 1,026 | 2,682 | 2,486 | ||||||||||||
Gross profit | 1,120 | 878 | 3,597 | 2,911 | ||||||||||||
Operating expenses: | ||||||||||||||||
Selling, general and administrative | 4,645 | 4,264 | 14,945 | 13,034 | ||||||||||||
Research and development | 1,726 | 871 | 3,847 | 2,620 | ||||||||||||
Total operating expenses | 6,371 | 5,135 | 18,792 | 15,654 | ||||||||||||
Loss from operations | (5,251 | ) | (4,257 | ) | (15,195 | ) | (12,743 | ) | ||||||||
Other income (expense), net | (19 | ) | 0 | (22 | ) | 0 | ||||||||||
Loss before income taxes | (5,270 | ) | (4,257 | ) | (15,217 | ) | (12,743 | ) | ||||||||
Income tax expense | (2 | ) | (3 | ) | (7 | ) | (7 | ) | ||||||||
Net loss | $ | (5,272 | ) | $ | (4,260 | ) | $ | (15,224 | ) | $ | (12,750 | ) | ||||
Basic and diluted loss per share | $ | (0.75 | ) | $ | (2.08 | ) | $ | (2.72 | ) | $ | (11.27 | ) | ||||
Weighted average shares outstanding – basic and diluted | 7,098 | 2,049 | 5,624 | 1,287 | ||||||||||||
Other comprehensive loss: | ||||||||||||||||
Foreign currency translation adjustments | $ | 0 | $ | (7 | ) | $ | (3 | ) | $ | (12 | ) | |||||
Total comprehensive loss | $ | (5,272 | ) | $ | (4,267 | ) | $ | (15,227 | ) | $ | (12,762 | ) |
Three months ended March 31, | ||||||||
2021 | 2020 | |||||||
Net sales | $ | 1,918 | $ | 1,630 | ||||
Cost of goods sold | 952 | 796 | ||||||
Gross margin | 966 | 834 | ||||||
Operating expenses: | ||||||||
Selling, general and administrative | 5,237 | 4,537 | ||||||
Research and development | 947 | 864 | ||||||
Total operating expenses | 6,184 | 5,401 | ||||||
Loss from operations | (5,218 | ) | (4,567 | ) | ||||
Other income (expense), net | (1 | ) | 1 | |||||
Loss before income taxes | (5,219 | ) | (4,566 | ) | ||||
Income tax expense | (2 | ) | (2 | ) | ||||
Net loss | $ | (5,221 | ) | $ | (4,568 | ) | ||
Basic and diluted loss per share | $ | (1.25 | ) | $ | (11.54 | ) | ||
Weighted average shares outstanding – basic and diluted | 4,212 | 548 | ||||||
Other comprehensive loss: | ||||||||
Foreign currency translation adjustments | $ | (3 | ) | $ | (3 | ) | ||
Total comprehensive loss | $ | (5,224 | ) | $ | (4,571 | ) |
Outstanding Shares of Common Stock | Common Stock | Additional Paid in Capital | Accumulated Other Comprehensive Income | Accumulated Deficit | Stockholders’ Equity | Outstanding Shares of Common Stock | Common Stock | Additional Paid in Capital | Accumulated Other Comprehensive Income | Accumulated Deficit | Stockholders’ Equity | |||||||||||||||||||||||||||||||||||||
Balance December 31, 2019 | 155,802 | $ | — | $ | 218,278 | $ | 1,214 | $ | (217,502 | ) | $ | 1,990 | 155,802 | $ | 0 | $ | 218,278 | $ | 1,214 | $ | (217,502 | ) | $ | 1,990 | ||||||||||||||||||||||||
Net loss | — | — | — | — | (4,568 | ) | (4,568 | ) | — | 0 | 0 | 0 | (4,568 | ) | (4,568 | ) | ||||||||||||||||||||||||||||||||
Foreign currency translation adjustment | — | — | — | (3 | ) | — | (3 | ) | — | 0 | 0 | (3 | ) | 0 | (3 | ) | ||||||||||||||||||||||||||||||||
Stock-based compensation and stock awards, net | — | — | 380 | — | — | 380 | ||||||||||||||||||||||||||||||||||||||||||
Stock-based compensation, net | 0 | 0 | 380 | 0 | 0 | 380 | ||||||||||||||||||||||||||||||||||||||||||
Issuance of common and preferred stock, net | 340,261 | — | 9,616 | — | — | 9,616 | 340,261 | 0 | 9,616 | 0 | 0 | 9,616 | ||||||||||||||||||||||||||||||||||||
Exercise of warrants | 29,933 | — | 289 | — | — | 289 | 29,933 | 0 | 289 | 0 | 0 | 289 | ||||||||||||||||||||||||||||||||||||
Conversion of preferred stock into common stock | 378,751 | — | — | — | — | — | 378,751 | 0 | 0 | 0 | 0 | 0 | ||||||||||||||||||||||||||||||||||||
Balance March 31, 2020 | 904,747 | $ | — | $ | 228,563 | $ | 1,211 | $ | (222,070 | ) | $ | 7,704 | 904,747 | $ | 0 | $ | 228,563 | $ | 1,211 | $ | (222,070 | ) | $ | 7,704 | ||||||||||||||||||||||||
Outstanding Shares of Common Stock | Common Stock | Additional Paid in Capital | Accumulated Other Comprehensive Loss | Accumulated Deficit | Stockholders’ Equity | |||||||||||||||||||||||||||||||||||||||||||
Balance December 31, 2020 | 2,736,060 | $ | — | $ | 249,663 | $ | (7 | ) | $ | (233,338 | ) | $ | 16,318 | |||||||||||||||||||||||||||||||||||
Net loss | — | — | — | — | (5,221 | ) | (5,221 | ) | — | 0 | 0 | 0 | (3,922 | ) | (3,922 | ) | ||||||||||||||||||||||||||||||||
Foreign currency translation adjustment | — | — | — | (3 | ) | — | (3 | ) | — | 0 | 0 | (2 | ) | 0 | (2 | ) | ||||||||||||||||||||||||||||||||
Stock-based compensation, net | — | — | 355 | — | — | 355 | 0 | 0 | 347 | 0 | 0 | 347 | ||||||||||||||||||||||||||||||||||||
Issuance of common stock, net | 3,795,816 | — | 18,902 | — | — | 18,902 | 290,938 | 0 | 3,424 | 0 | 0 | 3,424 | ||||||||||||||||||||||||||||||||||||
Exercise of warrants | 66 | — | 1 | — | — | 1 | 227,939 | 0 | 2,051 | 0 | 0 | 2,051 | ||||||||||||||||||||||||||||||||||||
Balance March 31, 2021 | 6,531,942 | $ | — | $ | 268,921 | $ | (10 | ) | $ | (238,559 | ) | $ | 30,352 | |||||||||||||||||||||||||||||||||||
Conversion of preferred stock into common stock | 16,270 | 0 | 0 | 0 | 0 | 0 | ||||||||||||||||||||||||||||||||||||||||||
Balance June 30, 2020 | 1,439,894 | $ | 0 | $ | 234,385 | $ | 1,209 | $ | (225,992 | ) | $ | 9,602 | ||||||||||||||||||||||||||||||||||||
Net loss | — | 0 | 0 | 0 | (4,260 | ) | (4,260 | ) | ||||||||||||||||||||||||||||||||||||||||
Foreign currency translation adjustment | — | 0 | 0 | (7 | ) | 0 | (7 | ) | ||||||||||||||||||||||||||||||||||||||||
Stock-based compensation, net | 0 | 0 | 310 | 0 | 0 | 310 | ||||||||||||||||||||||||||||||||||||||||||
Issuance of common stock, net | 1,064,678 | 0 | 12,908 | 0 | 0 | 12,908 | ||||||||||||||||||||||||||||||||||||||||||
Exercise of warrants | 197,267 | 0 | 1,775 | 0 | 0 | 1,775 | ||||||||||||||||||||||||||||||||||||||||||
Conversion of preferred stock into common stock | 34,221 | 0 | 0 | 0 | 0 | 0 | ||||||||||||||||||||||||||||||||||||||||||
Balance September 30, 2020 | 2,736,060 | $ | 0 | $ | 249,378 | $ | 1,202 | $ | (230,252 | ) | $ | 20,328 |
Outstanding Shares of Common Stock | Common Stock | Additional Paid in Capital | Accumulated Other Comprehensive Loss | Accumulated Deficit | Stockholders’ Equity | |||||||||||||||||||
Balance December 31, 2020 | 2,736,060 | $ | 0 | $ | 249,663 | $ | (7 | ) | $ | (233,338 | ) | $ | 16,318 | |||||||||||
Net loss | — | 0 | 0 | 0 | (5,221 | ) | (5,221 | ) | ||||||||||||||||
Foreign currency translation adjustment | — | 0 | 0 | (3 | ) | 0 | (3 | ) | ||||||||||||||||
Stock-based compensation, net | 0 | 0 | 355 | 0 | 0 | 355 | ||||||||||||||||||
Issuance of common stock, net | 3,795,816 | 0 | 18,902 | 0 | 0 | 18,902 | ||||||||||||||||||
Exercise of warrants | 66 | 0 | 1 | 0 | 0 | 1 | ||||||||||||||||||
Balance March 31, 2021 | 6,531,942 | $ | 0 | $ | 268,921 | $ | (10 | ) | $ | (238,559 | ) | $ | 30,352 | |||||||||||
Net loss | — | 0 | 0 | 0 | (4,731 | ) | (4,731 | ) | ||||||||||||||||
Foreign currency translation adjustment | — | 0 | 0 | 0 | 0 | 0 | ||||||||||||||||||
Stock-based compensation, net | 0 | 0 | 381 | 0 | 0 | 381 | ||||||||||||||||||
Issuance costs related to common stock offerings | — | 0 | (6 | ) | 0 | 0 | (6 | ) | ||||||||||||||||
Exercise of warrants | 76 | 0 | 0 | 0 | 0 | 0 | ||||||||||||||||||
Balance June 30, 2021 | 6,532,018 | $ | 0 | $ | 269,296 | $ | (10 | ) | $ | (243,290 | ) | $ | 25,996 | |||||||||||
Net loss | — | 0 | 0 | 0 | (5,272 | ) | (5,272 | ) | ||||||||||||||||
Foreign currency translation adjustment | — | 0 | 0 | 0 | 0 | 0 | ||||||||||||||||||
Stock-based compensation, net | 0 | 0 | 257 | 0 | 0 | 257 | ||||||||||||||||||
Issuance of common stock, net | 4,005,588 | 1 | 8,999 | 0 | 0 | 9,000 | ||||||||||||||||||
Balance September 30, 2021 | 10,537,606 | $ | 1 | $ | 278,552 | $ | (10 | ) | $ | (248,562 | ) | $ | 29,981 |
Three months ended March 31, | Nine months ended September 30, | |||||||||||||||
2021 | 2020 | 2021 | 2020 | |||||||||||||
Operating Activities: | ||||||||||||||||
Net loss | $ | (5,221 | ) | $ | (4,568 | ) | $ | (15,224 | ) | $ | (12,750 | ) | ||||
Adjustments to reconcile net loss to cash flows used in operating activities: | ||||||||||||||||
Depreciation and amortization | 126 | 65 | 383 | 253 | ||||||||||||
Stock-based compensation expense, net | 355 | 380 | 993 | 1,036 | ||||||||||||
Loss on disposal of property and equipment | — | 46 | 0 | 46 | ||||||||||||
Changes in operating assets and liabilities: | ||||||||||||||||
Accounts receivable | (14 | ) | 72 | (164 | ) | (249 | ) | |||||||||
Inventory | (89 | ) | (398 | ) | (105 | ) | (1,371 | ) | ||||||||
Other current assets | (132 | ) | 20 | (183 | ) | (74 | ) | |||||||||
Other assets and liabilities | 24 | 67 | 279 | 112 | ||||||||||||
Accounts payable and accrued expenses | (431 | ) | (1,179 | ) | 333 | (166 | ) | |||||||||
Net cash used in operating activities | (5,382 | ) | (5,495 | ) | (13,688 | ) | (13,163 | ) | ||||||||
Investing Activities: | ||||||||||||||||
Purchases of property and equipment | (56 | ) | (17 | ) | (191 | ) | (207 | ) | ||||||||
Net cash used in investing activities | (56 | ) | (17 | ) | (191 | ) | (207 | ) | ||||||||
Financing Activities: | ||||||||||||||||
Proceeds from public stock offerings, net | 18,902 | 9,616 | 27,896 | 25,949 | ||||||||||||
Proceeds from warrant exercises | 1 | 289 | 1 | 4,115 | ||||||||||||
Payments on finance lease liability | (6 | ) | — | (21 | ) | (14 | ) | |||||||||
Net cash provided by financing activities | 18,897 | 9,905 | 27,876 | 30,050 | ||||||||||||
Effect of exchange rate changes on cash | (3 | ) | (3 | ) | (3 | ) | (12 | ) | ||||||||
Net increase in cash and cash equivalents | 13,456 | 4,390 | 13,994 | 16,668 | ||||||||||||
Cash and cash equivalents - beginning of period | 14,437 | 1,279 | 14,437 | 1,279 | ||||||||||||
Cash and cash equivalents - end of period | $ | 27,893 | $ | 5,669 | $ | 28,431 | $ | 17,947 | ||||||||
Supplemental cash flow information | ||||||||||||||||
Inventory transferred to property, plant and equipment | $ | 89 | $ | — | $ | 257 | $ | 247 | ||||||||
Equipment acquired through finance lease liability | $ | 0 | $ | 98 |
( in thousands) | March 31, 2021 | December 31, 2020 | ||||||
Finished Goods | $ | 1,232 | $ | 1,343 | ||||
Work in Process | 315 | 342 | ||||||
Raw Materials | 1,410 | 1,272 | ||||||
Total | $ | 2,957 | $ | 2,957 |
( in thousands) | September 30, 2021 | December 31, 2020 | ||||||
Finished Goods | $ | 1,227 | $ | 1,343 | ||||
Work in Process | 268 | 342 | ||||||
Raw Materials | 1,310 | 1,272 | ||||||
Total | $ | 2,805 | $ | 2,957 |
March 31 | ||||||||
2021 | 2020 | |||||||
Warrants to purchase common stock | 1,631,882 | 925,869 | ||||||
Series H convertible preferred stock | — | 16,264 | ||||||
Series F convertible preferred stock | 23,114 | 48,720 | ||||||
Stock options | 140,471 | 13,995 | ||||||
Total | 1,795,467 | 1,004,848 |
September 30 | ||||||||
2021 | 2020 | |||||||
Warrants to purchase common stock | 1,631,801 | 1,631,948 | ||||||
Series F convertible preferred stock | 50,800 | 14,224 | ||||||
Stock options | 738,946 | 15,757 | ||||||
Total | 2,421,547 | 1,661,929 |
(in thousands, except per share amounts) | 2021 | 2020 | ||||||
Net loss | $ | (5,221 | ) | $ | (4,568 | ) | ||
Deemed dividend to preferred shareholders (see Note 3) | (33 | ) | (1,757 | ) | ||||
Net loss after deemed dividend | (5,254 | ) | (6,325 | ) | ||||
Weighted average shares outstanding | 4,212 | 548 | ||||||
Basic and diluted loss per share | $ | (1.25 | ) | $ | (11.54 | ) |
(in thousands, except per share amounts) | 2021 | 2020 | ||||||
Net loss | $ | (15,224 | ) | $ | (12,750 | ) | ||
Deemed dividend to preferred shareholders (see Note 3) | (75 | ) | (1,757 | ) | ||||
Net loss after deemed dividend | (15,299 | ) | (14,507 | ) | ||||
Weighted average shares outstanding | 5,624 | 1,287 | ||||||
Basic and diluted loss per share | $ | (2.72 | ) | $ | (11.27 | ) |
Three-months ended March 31, | Three months ended September 30, | Nine months ended September 30, | ||||||||||||||||||||||
(in thousands) | 2021 | 2020 | 2021 | 2020 | 2021 | 2020 | ||||||||||||||||||
Selling, general and administrative expense | $ | 327 | $ | 354 | $ | 216 | $ | 288 | $ | 894 | $ | 963 | ||||||||||||
Research and development expense | 28 | 26 | 40 | 21 | 99 | 73 | ||||||||||||||||||
Total stock-based compensation expense | $ | 355 | $ | 380 | $ | 256 | $ | 309 | $ | 993 | $ | 1,036 |
Three Months Ended March 31, 2021 | Three Months Ended March 31, 2020 | Increase (Decrease) | % Change | |||||||||||||||||||||||||
Three Months Ended September 30, 2021 | Three Months Ended September 30, 2021 | Three Months Ended September 30, 2020 | Increase (Decrease) | % Change | ||||||||||||||||||||||||
$ | 1,918 | $ | 1,630 | $ | 288 | 17.7 | % | 1,853 | $ | 1,904 | $ | (51 | ) | (2.7 | )% |
(in thousands) | Three Months Ended September 30, 2021 | Three Months Ended September 30, 2020 | Increase (Decrease) | % Change | ||||||||||||
Cost of goods sold | $ | 733 | $ | 1,026 | $ | (293 | ) | (28.6 | )% | |||||||
Selling, general and administrative | $ | 4,645 | $ | 4,264 | $ | 381 | 8.9 | % | ||||||||
Research and development | $ | 1,726 | $ | 871 | $ | 855 | 98.2 | % |
Nine Months Ended September 30, 2021 | Nine Months Ended September 30, 2020 | Increase (Decrease) | % Change | |||||||||||
$ | 6,279 | $ | 5,397 | $ | 882 | 16.3 | % |
(in thousands) | Three Months Ended March 31, 2021 | Three Months Ended March 31, 2020 | Increase (Decrease) | % Change | Nine Months Ended September 30, 2021 | Nine Months Ended September 30, 2020 | Increase (Decrease) | % Change | ||||||||||||||||||||||||||||
Cost of goods sold | $ | 952 | $ | 796 | $ | 156 | 19. | 6 | % | $ | 2,682 | $ | 2,486 | $ | 196 | 7.9 | % | |||||||||||||||||||
Selling, general and administrative | $ | 5,237 | $ | 4,537 | $ | 700 | 15. | 4 | % | $ | 14,945 | $ | 13,034 | $ | 1,911 | 14.7 | % | |||||||||||||||||||
Research and development | $ | 947 | $ | 864 | $ | 83 | 9.6 | % | $ | 3,847 | $ | 2,620 | $ | 1,227 | 46.8 | % |
ITEM 3. |
ITEM 4. |
ITEM 1A. |
ITEM 2. |
ITEM 3. |
ITEM 4. |
ITEM 5. |
ITEM 6. | EXHIBITS |
Incorporated By Reference | |||||||||||||
Exhibit Number | Exhibit Description | Form | File Number | Date of First Filing | Exhibit Number | Filed Herewith | Furnished Herewith | ||||||
Fourth Amended and Restated Certificate of Incorporation | 10 | 001-35312 | February 1, 2012 | 3.1 | |||||||||
Certificate of Amendment to the Fourth Amended and Restated Certificate of Incorporation | 8-K | 001-35312 | January 13, 2017 | 3.1 | |||||||||
Certificate of Amendment to the Fourth Amended and Restated Certificate of Incorporation | 8-K | 001-35312 | May 23, 2017 | 3.1 | |||||||||
Certificate of Amendment to the Fourth Amended and Restated Certificate of Incorporation | 8-K | 001-35312 | October 12, 2017 | 3.1 | |||||||||
Certificate of Amendment to Fourth Amended and Restated Certificate of Incorporation | 8-K/A | 001-35312 | October 16, 2020 | 3.1 | |||||||||
Certificate of Amendment to Fourth Amended and Restated Certificate of Incorporation | 8-K | 001-35312 | January 2, 2019 | 3.1 | |||||||||
Certificate of Amendment to Fourth Amended and Restated Certificate of Incorporation | 8-K | 001-35312 | April 27, 2021 | 3.1 | |||||||||
Form of Certificate of Designation of Series A Junior Participating Preferred Stock | 8-K | 001-35312 | June 14, 2013 | 3.1 | |||||||||
Form of Certificate of Designation of Preferences, Rights and Limitations of Series F Convertible Preferred Stock | S-1/A | 333-221010 | November 17, 2017 | 3.7 | |||||||||
Certificate of Designation of Preferences, Rights and Limitations of Series G Convertible Preferred Stock | 8-K | 001-35312 | March 13, 2019 | 3.1 | |||||||||
Certificate of Designation of Preferences, Rights and Limitations of Series H Convertible Preferred Stock | 8-K | 001-35312 | January 29, 2020 | 3.1 | |||||||||
Second Amended and Restated Bylaws | 8-K | 001-35312 | April 27, 2021 | 3.2 |
Incorporated By Reference | |||||||||||||
Exhibit Number | Exhibit Description | Form | File Number | Date of First Filing | Exhibit Number | Filed Herewith | Furnished Herewith | ||||||
Fourth Amended and Restated Certificate of Incorporation | 10 | 001-35312 | February 1, 2012 | 3.1 | |||||||||
Certificate of Amendment to the Fourth Amended and Restated Certificate of Incorporation | 8-K | 001-35312 | January 13, 2017 | 3.1 | |||||||||
Certificate of Amendment to the Fourth Amended and Restated Certificate of Incorporation | 8-K | 001-35312 | May 23, 2017 | 3.1 | |||||||||
Certificate of Amendment to the Fourth Amended and Restated Certificate of Incorporation | 8-K | 001-35312 | October 12, 2017 | 3.1 | |||||||||
Certificate of Amendment to the Fourth Amended and Restated Certificate of Incorporation | 8-K | 001-35312 | January 2, 2019 | 3.1 | |||||||||
Certificate of Amendment to the Fourth Amended and Restated Certificate of Incorporation | 8-K/A | 001-35312 | October 16, 2020 | 3.1 | |||||||||
Certificate of Amendment to the Fourth Amended and Restated Certificate of Incorporation | 8-K | 001-35312 | April 27, 2021 | 3.1 | |||||||||
Certificate of Designation of Series A Junior Participating Preferred Stock | 8-K | 001-35312 | June 14, 2013 | 3.1 | |||||||||
Certificate of Designation of Preferences, Rights and Limitations of Series F Convertible Preferred Stock | S-1/A | 333-221010 | November 6, 2017 | 3.7 | |||||||||
Certificate of Designation of Preferences, Rights and Limitations of Series G Convertible Preferred Stock | 8-K | 001-35312 | March 13, 2019 | 3.1 | |||||||||
Certificate of Designation of Preferences, Rights and Limitations of Series H Convertible Preferred Stock | 8-K | 001-35312 | January 29, 2020 | 3.1 | |||||||||
Second Amended and Restated Bylaws | 8-K | 001-35312 | April 27, 2021 | 3.2 | |||||||||
Underwriting Agreement, dated September 15, 2021, between Nuwellis, Inc. and Ladenburg Thalmann & Co. Inc., as the Representative of the several underwriters named in Schedule I thereto | 8-K | 001-35312 | September 17, 2021 | 1.1 |
Incorporated By Reference | | ||||||||||||
Exhibit Number | Exhibit Description | Form | File Number | Date of First Filing | Exhibit Number | Filed Herewith | Furnished Herewith | ||||||
Nuwellis, Inc. Non-Employee Director Compensation Policy (effective August 18, 2021) | X | ||||||||||||
Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | X | ||||||||||||
Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | X | ||||||||||||
Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | X | ||||||||||||
Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | X | ||||||||||||
101.INS | Inline XBRL Instance Document | X | |||||||||||
101.SCH | Inline XBRL Taxonomy Extension Schema Document | X | |||||||||||
101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document | X | |||||||||||
101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document | X | |||||||||||
101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document | X | |||||||||||
101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document | X | |||||||||||
104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) | X |
Nuwellis, Inc. | |||
Date: | By: | /s/ Nestor Jaramillo, Jr. | |
Nestor Jaramillo, Jr. | |||
President, Chief Executive Officer | |||
(principal executive officer) |
Date: November 10, 2021 | By: | /s/ George Montague | |
George Montague | |||
Chief Financial Officer | |||
(principal | |||